Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: KEGG:D01817 (Iohexol)
 504 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Hepatic angiography was performed in a double-blind two-group study in 60 patients using iohexol 350 mg I/ml and metrizoate 350 mg I/ml. A slight increase in serum values of hepatic enzymes was found when metrizoate was used, particularly in patients with impaired liver function. Iohexol gave considerably less pain and sensation of heat than did metrizoate. A non-expected significant increase of creatine kinase was recorded when iohexol was used. The reason for this is not yet known.
 ...
PMID:Effects of metrizoate and iohexol on the liver at visceral angiography. 296 3

In order to compare tolerability and radiographic properties of Omnipaque (iohexol) 350 mg I/ml and Urografin (sodium meglumine diatrizoate) 76% (370 mg I/ml) in left ventriculography and coronary arteriography, a randomised, double-blind parallel study was conducted. ECG, heart rate, blood pressure, cardiac output, oxygen saturation, CK-MB, adverse reactions and opacification were recorded. Twenty-five patients received Omnipaque and 24 Urografin and all patients were included in the final material. Omnipaque was found to have less influence on haemodynamics than Urografin. Few adverse reactions were encountered in the entire study, but fewer after injections of Omnipaque than after Urografin. Equally good opacification was demonstrated for both media. Omnipaque was found well suited for cardioangiography and superior to standard ionic media.
 ...
PMID:Omnipaque and Urografin in left ventriculography and coronary arteriography. A randomised, double blind study. 390 99

A nonionic contrast medium (iohexol) was evaluated for safety and efficacy in pediatric angiocardiography in this study of 15 patients, age 6 to 82 months. Patients carried a preliminary diagnosis of congenital heart disease. Subjects were injected with iohexol, 350 mg iodine/ml of solution with an average volume of 2.46 ml/kg of body weight at a rate of 9 to 14.5 ml/sec. The parameters evaluated included vital signs, intravascular BP, ECG changes, discomfort, and adverse reactions. No adverse reactions were noted in 14 of 15 patients. No significant changes in axillary temperature of ECG were observed. Intravascular blood pressure showed only moderate changes. After 24 hours, creatine phosphokinase (CPK) plasma concentrations increased significantly. Serum electrolytes remained unchanged. Image quality was deemed excellent considering variations in injection site and flow condition of the heart. Iohexol caused remarkably little discomfort and no adverse effects.
 ...
PMID:Pediatric angiocardiography with iohexol. 397 30